Paunovich Vukasin sold $482K of LFST

Paunovich Vukasin (Chief Technology Officer) sold 44,394 shares of LifeStance Health Group, Inc. (LFST) at $10.85 ($0.48M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Paunovich Vukasin
Published Aug 12, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LFST
Neutral
high confidence
Mentioned
$LFST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

The disclosed event is an officer open-market sale of common stock, pre-arranged under Rule 10b5-1, which typically reduces interpretive weight versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

The article does not disclose any offsetting insider buys, changes in guidance, or operational developments; without those, the trading signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-12 after-hours; sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for LifeStance Health Group, Inc.

Company-level read

Ticker impact

$LFSTNeutralHigh confidence
Context

LifeStance Health Group CTO Paunovich Vukasin sold 44,394 shares at $10.8500 on 2026-08-10 under a 10b5-1 plan, per Form 4.

Expected impact

Low near-term impact; any reaction is likely limited and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 open-market sale with an explicitly pre-arranged 10b5-1 plan, providing limited new information about near-term business performance.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so any negative interpretation may be overstated.

Key entities

  • LifeStance Health Group, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Paunovich Vukasin

    Chief Technology Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LFSTMed

BMO raises Lifestance Health stock price target on strong results

BMO Capital raised its price target on Lifestance Health (LFST) to $16.00, citing strong Q3 results. Revenue beat estimates by 5.6%, and EBITDA exceeded by 23.6%. The company raised its full-year outlook, but expects a sequential EBITDA decline due to reinvestment. LFST trades at $13.43 with a $5.1B market cap. The company also announced Q3 2026 earnings, surpassing expectations with a 25% revenue increase.

$LFSTMed

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.

$LFSTMed

LifeStance Health Group Inc (LFST) (Q3 2026) Earnings Call Highlights: Revenue Jumps 25%

LifeStance Health (LFST) reported 25% revenue growth in Q3 2026. The company expects EHR implementation to reduce 2027 revenue growth by 1-2% and cost $20-30M. Clinician retention is stable, but new clinician retention is low. Q4 adjusted EBITDA guidance suggests a sequential decline due to planned investments. Specialty services, including Spravato, are growing but face variable payer reimbursement. Management remains optimistic about long-term margin expansion and clinician growth.

$LFSTHighAI 8/10

LifeStance (LFST) Q3 2026 Earnings Call Transcript

LifeStance (LFST) reported Q3 2026 revenue growth of 25% to $456M, driven by increased visit volumes and higher revenue per visit. The company expanded its clinician base by 11% and opened 8 new centers. It also raised full-year revenue guidance to $1.741B-$1.761B. LifeStance highlighted strong results in specialty services for treatment-resistant depression and plans to invest in strategic priorities. The company expects temporary revenue growth impact in 2027 due to EHR implementation.

$LFSTMed

LifeStance Health: Q3 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q3 net income of $22.4M, or 6 cents per share, beating estimates. Revenue was $455.9M, also exceeding forecasts. The company expects Q4 revenue of $446M-$466M and full-year revenue of $1.74B-$1.76B.